Skip to main content
. Author manuscript; available in PMC: 2019 Aug 19.
Published in final edited form as: Drug Discov Today Technol. 2018 Feb 4;28:53–61. doi: 10.1016/j.ddtec.2018.01.001

Figure 2. CRISPR-based applications with nuclease-deficient Cas9 (dCas9).

Figure 2.

dCas9 serves as a sequence-directed genome target platform. Fusing dCas9 to different functional domains allows for a wide range of applications, including transcriptional up-regulation (with transcriptional activators) and down-regulation (with transcriptional repressors) (A), adding (with epigenetic writers) or removing (with epigenetic erasers) epigenetic marks (B), and visualization of specific genomic regions (C).